Xilio Therapeutics, Inc. (XLO)

9.00 -0.11% (-0.01)

Over 1Y: -7.0%

2026-08-28
Style
Area Line Line with markers Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

8 10 12
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 19.1M Q3 '25 — Operating Cash Flow: -17.5M Q3 '25 — Free Cash Flow: -17.5M Q3 '25 — Net Income: -16.3M Q4 '25 — Revenue: 13.7M Q4 '25 — Operating Cash Flow: -2M Q4 '25 — Free Cash Flow: -2.1M Q4 '25 — Net Income: 10.4M Q1 '26 — Revenue: 12.6M Q1 '26 — Operating Cash Flow: -22.3M Q1 '26 — Free Cash Flow: -22.9M Q1 '26 — Net Income: -9.5M Q2 '26 — Revenue: 18.7M Q2 '26 — Operating Cash Flow: -18.8M Q2 '26 — Free Cash Flow: -18.8M Q2 '26 — Net Income: -6.4M -18M -9M 0 9M 18M 27M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.9
SBC / sales 12.3%
OE margin -107.9%
Oper. margin -48.9%
Accruals 25.1%
EBITDA margin -46.9%
FCF margin -95.6%
OCF margin -94.5%
Profit margin -34.1%
ROA -14.2%
ROCE -26.1%
ROE -30.2%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

8.9
RPO / sales 0.35×
RPO growth —
Segment HHI —

1 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.2
Current ratio 12.5×
ND/EBITDA —
Cash runway 2.2 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 4.3×
F-score 5.1 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

10.0
Sales/sh Y/Y +95.3%
Sales Q/Q +131.2%
Shares change +118.8%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.